BBRAUN SE_GREEN (1).jpg
B. Braun Medical Acquires NxStage Medical, Inc.’s Streamline Bloodlines
February 25, 2019 13:54 ET | B. Braun Medical Inc.--US
BETHLEHEM, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. is pleased to announce the acquisition of the Medisystems® Streamline® Bloodlines business. The acquired bloodline systems...
gmi 2018.png
Continuous Renal Replacement Therapy Market to exceed $1.3 billion by 2024: Global Market Insights, Inc.
November 19, 2018 06:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Global Continuous Renal Replacement Therapy Market will surpass USD 1.3 billion by 2024; according to a new research report by Global...
Advent Access logo
ADVENT ACCESS ACQUIRES Vwing™ VASCULAR NEEDLE GUIDE FROM VITAL ACCESS TO CREATE LEADING PORTFOLIO OF VASCULAR ACCESS SOLUTIONS FOR DIALYSIS
October 04, 2018 06:00 ET | Advent Access
Singapore, Oct. 04, 2018 (GLOBE NEWSWIRE) --   -- Advent’s IP portfolio now one of the industry’s most extensive in technology-assisted use of AV fistulas-- Acquisition provides access to key US...
av-guardian
ADVENT ACCESS COMPLETES CE MARK SUBMISSION FOR av-GuardianTM
September 20, 2018 06:00 ET | Advent Access
Singapore, Sept. 20, 2018 (GLOBE NEWSWIRE) --   Singapore, 20 September 2018 – Advent Access (Advent), one of Singapore’s most innovative medtech companies, today announced that it has...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd
June 15, 2016 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
rockwell-logo2.jpg
U.S. FDA Approves Rockwell’s Triferic® Powder Packet for Treating Anemia in Hemodialysis Patients
April 26, 2016 08:00 ET | Rockwell Medical, Inc.
WIXOM, Mich., April 26, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for Hemodialysis
March 26, 2015 19:00 ET | Proteon Therapeutics, Inc.
DALLAS and WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of...
Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis
October 15, 2014 11:39 ET | Wisconsin Alumni Research Foundation
MADISON, Wis., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Deltanoid Pharmaceuticals announces the successful completion of a phase 2B clinical trial for its lead experimental drug DP001 for the treatment of...